GNRH1 and prostate cancer: They reviewed retrospectively the cardiovascular adverse effects which occurred in patients with prostate cancer treated with GnRH agonists, GnRH antagonists, androgen receptor antagonists and/or androgen synthesis inhibitors between January 2000 and April 2020.